Search Within

Dana Elizabeth Rathkopf

  1. "GDMT, Radiation Oncology"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (1)
Groups
  1. Department of Medicine (9)
  2. GDMT, Radiation Oncology (9)
  3. Genitourinary Oncology Service (9)
  4. Gynecology Disease Management Team (9)
  5. Radiation Oncology, Department of (9)
  6. Solid Tumor Oncology Division (9)

More Groups

People
  1. Marisa Kollmeier (9)
  2. Han Xiao (4)
  3. Howard Scher (4)
  4. Sean McBride (4)
  5. Michael Zelefsky (3)
  6. Susan Slovin (3)

More People

Years
  1. 2024 (3)
  2. 2023 (2)
  3. 2022 (1)
  4. 2021 (1)
  5. 2019 (1)
  6. 2018 (1)
Publications
  1. Journal of Clinical Oncology (5)
  2. International Journal of Radiation Oncology, Biology, Physics (3)
  3. Journal of Urology (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. Elsevier Inc. (3)
  3. Elsevier Science, Inc. (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term patient-reported health-related quality of life in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH Agonist with either bicalutamide or abiraterone acetate plus prednisone and apalutamide after radical prostatectomy
    Meeting Abstract

    Hoffman, K. E.; Nguyen, P. L.; Rathkopf, D.; Zurita-Saavedra, A.; Spratt, D. E.; Dess, R. T.; Liauw, S.; Szmulewitz, R.; Einstein, D. J.; Bubley, G.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Testosterone Recovery and Associated Impact on PatientReported Health -Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial
    Meeting Abstract

    Moningi, S.; Nguyen, P. L.; Rathkopf, D.; Zurita-Saavedra, A.; Spratt, D. E.; Dess, R. T.; Liauw, S.; Szmulewitz, R.; Einstein, D. J.; Bubley, G.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP)
    Meeting Abstract

    Hoffman, K. E.; Nguyen, P. L.; Rathkopf, D. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; Bubley, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)
    Meeting Abstract

    Nguyen, P. L.; Kollmeier, M. A.; Rathkopf, D.; Hoffman, K. E.; Zurita-Saavedra, A.; Spratt, D. E.; Dess, R. T.; Liauw, S.; Szmulewitz, R.; Einstein, D. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)
    Meeting Abstract

    Nguyen, P. L.; Kollmeier, M.; Rathkopf, D. E.; Hoffman, K. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide
    Journal Article

    Pan, A.; Reingold, R. E.; Zhao, J. L.; Moy, A.; Kraehenbuehl, L.; Dranitsaris, G.; McBride, S. M.; Scher, H. I.; Kollmeier, M. A.; Xiao, H.; more...
    Journal of Urology (2022)

    Fulltext@MSK | Save
  • Interim results of AASUR: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA plus P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Spratt, D. E.; Kollmeier, M.; Abida, W.; Xiao, H.; Slovin, S. F.; Paller, C. J.; Deville, C.; Den, R. B.; Hearn, J. W. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients
    Meeting Abstract

    McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Paller, C. J.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W. D.; Den, R. B.; Deville, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W.; Den, R. B.; Deville, C.; Borofsky, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save